Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

ABSTRACT: Study with an investigational drug in patients with recurrent or non-responsive colorectal cancer or other advanced solid tumors. This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

DISEASE(S): Colorectal Cancer,Advanced Solid Tumors,Colorectal Neoplasms

PROVIDER: 2011963 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Project description:Curated publicly available nanopore datasets

| PRJNA932454 | ENA

Aligned Ancient Genomes

Project description:Alignment of publicly available ancient genomes to hg38

| PRJEB64654 | ENA

De novo peptide sequencing tools benchmark

Project description:Our study is a large-scale evaluation of de novo peptide sequencing tools using both publicly and proprietary heterogeneous datasets spanning multiple species, mass spectrometers, post-translational modifications, and a wide range of use cases. This dataset contains a publicly available subset of this dataset. The dataset includes raw MS/MS spectra in their original vendor formats as well as in mzML and Mascot Generic Format (MGF). Additionally, peptide spectral hits (PSMs) identified through a database search and rescoring workflow, along with the dataset-specific protein databases used for annotation, are provided.

2024-10-23 | MSV000096182 | MassIVE

Methanosphaera

Project description:Methanosphaera population genome binning from publicly available SRA datasets

| PRJNA362975 | ENA

Public data extends TB surveillance

Project description:Publicly available whole-genome sequencing data supports TB surveillance

| PRJEB35201 | ENA

A gene expression profile of BRCAness that is associated with outcome in ovarian cancer

Project description:A gene expression profile of BRCAness was defined in publicly available expression data of 61 patients with epithelial ovarian cancer (34 patients with BRCA-1 or BRCA-2 mutations and 27 patients with sporadic disease). This dataset is publicly available at http://jnci.oxfordjournals.org/cgi/content/full/94/13/990/DC1 The BRCAness profile was correlated with outcome in 70 patients with epithelial ovarian cancer and known outcome data.

2010-07-11 | GSE19829 | GEO

A gene expression profile of BRCAness that is associated with outcome in ovarian cancer

2010-07-11 | E-GEOD-19829 | biostudies-arrayexpress

Assembly of cell fusing agent virus from publicly available sequencing datasets

Project description:Assembly of cell fusing agent virus from publicly available sequencing datasets

| PRJEB33801 | ENA

Project description:Elucidating the population structure and diversity of publicly available pepper accessions

| PRJNA876725 | ENA

Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity

Project description:Drug Toxicity Signature Generation Center (DToxS) at the Icahn School of Medicine at Mount Sinai is an integral part of the NIH Library of Integrated Network-Based Cellular Signatures (LINCS) program. A key aim of DToxS is to generate both proteomic and transcriptomic signatures that cab predict adverse effects, especially cardiotoxicity, of drugs approved by the Food and Drug Administration. Towards this goal, high throughput shot-gun proteomics experiments (308 cell line/drug combinations + 64 HeLa control lysates + 9 auxiliary treatment samples) have been conducted at the Center for Advanced Proteomics Research at Rutgers-New Jersey Medical School. The integrated proteomic and transcriptomic signatures have been used for computational network analysis to identify cellular signatures of cardiotoxicity that may predict drug-induced toxicity and possible mitigation of such toxicities by mixing different drugs. Both raw and processed proteomics data have been carefully controlled for quality and have been made publicly available via the PRoteomics IDEntifications (PRIDE) database. As such, this broad drug-stimulated proteomic dataset is valuable for the prediction drug toxicities and their mitigation.

2021-10-18 | PXD014791 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data